Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numer...
Saved in:
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | 42527 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869522563697213440 |
|---|---|
| author | Reischl, Gerald |
| author_browse | Reischl, Gerald |
| author_facet | Reischl, Gerald |
| author_sort | Reischl, Gerald |
| collection | Directory of Open Access Books |
| description | This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences. |
| format | Online |
| id | doab-20.500.12854ir-60492 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-604922024-03-30T23:23:02Z Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine Reischl, Gerald R5-920 RM1-950 n/a pretargeting radioiodination neurodegeneration phosphoramidon GRPR molecular imaging allosteric modulator radiosynthesis separation ?-CIT. PET/CT imaging technetium-99m gastrin-releasing peptide receptor metabotropic glutamate receptor subtype 5 glutamate oncogenic fusions Fusarinine C hypoxia tirapazamine (TPZ) 68Ga sentinel lymph node 99mTc-radioligand iodine-131 electrophilic radioiodination 4-dioxide (BTDO) minigastrin ceftriaxone tropomyosin receptor kinase carbonic anhydrase IX ABP688 NPY(Y1)R MMPEP radiosensitizer neprilysin-inhibition radiochemistry girentuximab benzotriazine-1 gallium-68 cholecystokinin-2 receptor tumor targeting radioimmunotherapy salivary gland uptake metabolic stability tumor hypoxia multimerization oxidizing agent neuroinflammation gastrin-releasing peptide dextran carbon-11 peptide heterodimers apparent molar activity radiometals microglia rituximab [18F]FMISO [11C]meta-hydroxyephedrine Iodo-Gen® mannose 177Lu-radiopharmaceuticals azomycin nucleosides breast cancer click chemistry small animal imaging SR 4317 benzotriazine-1-monoxide (BTMO) bombesin prostate cancer Chloramine T 99mTc-radiopharmaceuticals ketamine PSMA-617 positron emission tomography hydrazinonicotinic acid (HYNIC) renal cell carcinomas [18F]PSS232 PET endoradiotherapy thema EDItEUR::M Medicine and Nursing This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences. 2021-02-12T05:15:14Z 2021-02-12T05:15:14Z 2019-12-09 11:49:15 2019 book 42527 9783039213139 9783039213146 https://directory.doabooks.org/handle/20.500.12854/60492 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/1555 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03921-314-6 10.3390/books978-3-03921-314-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039213139 9783039213146 214 open access |
| spellingShingle | R5-920 RM1-950 n/a pretargeting radioiodination neurodegeneration phosphoramidon GRPR molecular imaging allosteric modulator radiosynthesis separation ?-CIT. PET/CT imaging technetium-99m gastrin-releasing peptide receptor metabotropic glutamate receptor subtype 5 glutamate oncogenic fusions Fusarinine C hypoxia tirapazamine (TPZ) 68Ga sentinel lymph node 99mTc-radioligand iodine-131 electrophilic radioiodination 4-dioxide (BTDO) minigastrin ceftriaxone tropomyosin receptor kinase carbonic anhydrase IX ABP688 NPY(Y1)R MMPEP radiosensitizer neprilysin-inhibition radiochemistry girentuximab benzotriazine-1 gallium-68 cholecystokinin-2 receptor tumor targeting radioimmunotherapy salivary gland uptake metabolic stability tumor hypoxia multimerization oxidizing agent neuroinflammation gastrin-releasing peptide dextran carbon-11 peptide heterodimers apparent molar activity radiometals microglia rituximab [18F]FMISO [11C]meta-hydroxyephedrine Iodo-Gen® mannose 177Lu-radiopharmaceuticals azomycin nucleosides breast cancer click chemistry small animal imaging SR 4317 benzotriazine-1-monoxide (BTMO) bombesin prostate cancer Chloramine T 99mTc-radiopharmaceuticals ketamine PSMA-617 positron emission tomography hydrazinonicotinic acid (HYNIC) renal cell carcinomas [18F]PSS232 PET endoradiotherapy thema EDItEUR::M Medicine and Nursing Reischl, Gerald Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title | Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title_full | Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title_fullStr | Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title_full_unstemmed | Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title_short | Targets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine |
| title_sort | targets tracers and translation novel radiopharmaceuticals boost nuclear medicine |
| topic | R5-920 RM1-950 n/a pretargeting radioiodination neurodegeneration phosphoramidon GRPR molecular imaging allosteric modulator radiosynthesis separation ?-CIT. PET/CT imaging technetium-99m gastrin-releasing peptide receptor metabotropic glutamate receptor subtype 5 glutamate oncogenic fusions Fusarinine C hypoxia tirapazamine (TPZ) 68Ga sentinel lymph node 99mTc-radioligand iodine-131 electrophilic radioiodination 4-dioxide (BTDO) minigastrin ceftriaxone tropomyosin receptor kinase carbonic anhydrase IX ABP688 NPY(Y1)R MMPEP radiosensitizer neprilysin-inhibition radiochemistry girentuximab benzotriazine-1 gallium-68 cholecystokinin-2 receptor tumor targeting radioimmunotherapy salivary gland uptake metabolic stability tumor hypoxia multimerization oxidizing agent neuroinflammation gastrin-releasing peptide dextran carbon-11 peptide heterodimers apparent molar activity radiometals microglia rituximab [18F]FMISO [11C]meta-hydroxyephedrine Iodo-Gen® mannose 177Lu-radiopharmaceuticals azomycin nucleosides breast cancer click chemistry small animal imaging SR 4317 benzotriazine-1-monoxide (BTMO) bombesin prostate cancer Chloramine T 99mTc-radiopharmaceuticals ketamine PSMA-617 positron emission tomography hydrazinonicotinic acid (HYNIC) renal cell carcinomas [18F]PSS232 PET endoradiotherapy thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RM1-950 n/a pretargeting radioiodination neurodegeneration phosphoramidon GRPR molecular imaging allosteric modulator radiosynthesis separation ?-CIT. PET/CT imaging technetium-99m gastrin-releasing peptide receptor metabotropic glutamate receptor subtype 5 glutamate oncogenic fusions Fusarinine C hypoxia tirapazamine (TPZ) 68Ga sentinel lymph node 99mTc-radioligand iodine-131 electrophilic radioiodination 4-dioxide (BTDO) minigastrin ceftriaxone tropomyosin receptor kinase carbonic anhydrase IX ABP688 NPY(Y1)R MMPEP radiosensitizer neprilysin-inhibition radiochemistry girentuximab benzotriazine-1 gallium-68 cholecystokinin-2 receptor tumor targeting radioimmunotherapy salivary gland uptake metabolic stability tumor hypoxia multimerization oxidizing agent neuroinflammation gastrin-releasing peptide dextran carbon-11 peptide heterodimers apparent molar activity radiometals microglia rituximab [18F]FMISO [11C]meta-hydroxyephedrine Iodo-Gen® mannose 177Lu-radiopharmaceuticals azomycin nucleosides breast cancer click chemistry small animal imaging SR 4317 benzotriazine-1-monoxide (BTMO) bombesin prostate cancer Chloramine T 99mTc-radiopharmaceuticals ketamine PSMA-617 positron emission tomography hydrazinonicotinic acid (HYNIC) renal cell carcinomas [18F]PSS232 PET endoradiotherapy thema EDItEUR::M Medicine and Nursing |
| url | 42527 |
| work_keys_str_mv | AT reischlgerald targetstracersandtranslationnovelradiopharmaceuticalsboostnuclearmedicine |